Hematopoietic stem cells are widely recognized as attractconditions employed, Ͼ75% of the target cells retained the ive targets for gene therapy but current protocols to trans-CD34 + Lin − primitive phenotype after 4-5 days in culture; of duce these cells using recombinant retroviral vectors are those у25% expressed a high level of GFP detectable by inefficient. To evaluate optimization of retroviral transducboth flow cytometric analysis and fluorescence tion of hematopoietic stem cells and stability of gene microscopy. When transduced cells were cultured in clonexpression in their progeny, the green fluorescent protein ogenic progenitor assays, GFP fluorescence was readily (GFP) was explored as a reporter. We first improved sensidetected in situ, indicating that GFP expression was stable tivity of detection Ͼ100-fold over that achieved previously and not detrimental to the differentiative potential of the by using a novel retroviral vector (termed MGIN) expresstransduced CD34 + Lin − cells. We conclude that GFP is ing a high level of an enhanced GFP gene. Primitive effective as a vital marker to quantify retrovirus-mediated human hematopoietic cells bearing the CD34 surface gene transfer into human hematopoietic and perhaps antigen and lacking lineage differentiation markers other types of stem/progenitor cells, and monitor (CD34 + Lin − ) were transduced with the MGIN vector using gene expression during their subsequent cell lineage a clinically applicable supernatant procedure. Under the determinations.Keywords: gene therapy; gene transfer; gene expression; retroviral vectors; GFP; hematopoietic stem cells HSPC, the second problem associated with retroviral vecIntroduction tor-based gene therapy is low levels of sustained gene Hematopoietic stem and progenitor cells (HSPC) provide expression. Retroviral vectors derived from Moloney an attractive target for gene therapy because they have murine leukemia virus (MoMLV) are the most commonly the potential to continue producing progeny cells conused retroviral vectors in clinical trials. In a standard containing a therapeutic gene indefinitely. Hematological figuration, the gene of interest is placed under the trandiseases potentially benefiting from HSPC-based gene scriptional control of the viral long terminal repeat (LTR) therapy approaches include hereditary hemoglobinosince gene expression driven by LTR is generally higher pathies, immune deficiencies and disorders of phagocytic than by an internal promoter. 9,10 However, it has been cells, as well as other diseases such as acquired immunoreported that MLV LTR-mediated gene expression is fredeficiency syndrome and cancer. 1 Retroviral vectors, quently down-regulated during differentiation of which are being used in the majority of current clinical HSPC. 11,12 Because the LTR of the murine stem cell virus trials, are a primary choice as the vehicle for gene deliv-(MSCV) retroviral vector is permissive for expression in ery since they are capable of integrating into cellular murine HSPC, 8,13 we were interested...